Contract facts
FederalNo full NAICS 424210 intel page yet. Browse NAICS intelligence
4560560954!STELARA 90 MG/ML SYRINGEML is a federal award for Dla Troop Support held by Amerisourcebergen Drug Corp. Estimated value $130K ($130K obligated). Current period of performance ends Apr 13, 2023. Place of performance: CONSHOHOCKEN PA.
Recompete timing
PublicCurrent PoP ended Apr 13, 2023 (1226 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Incumbent footprint
Public recordAmerisourcebergen Drug Corp — $19.3B obligated across 1,357,999 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract SPE2DB23FC2CF?
SPE2DB23FC2CF (4560560954!stelara 90 MG ML syringeml) is a Dla Troop Support award with a potential value of $130K, currently held by Amerisourcebergen Drug Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded SPE2DB23FC2CF?
Dla Troop Support awarded SPE2DB23FC2CF to Amerisourcebergen Drug Corp (potential $130K).
Who is the incumbent on SPE2DB23FC2CF?
Amerisourcebergen Drug Corp is the incumbent with $19.3B across 1357999 related awards in SCOUT’s public footprint. The current period of performance ends Apr 13, 2023.
When does Amerisourcebergen Drug Corp’s SPE2DB23FC2CF come up for recompete?
SCOUT tracks a period-of-performance end of Apr 13, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.